{
    "nct_id": "NCT03463473",
    "official_title": "First-in-human, Open-label, Phase 1 Dose-Escalation Study of MSB2311, A Humanized Anti-PD-L1 Monoclonal Antibody in Subjects With Advanced Solid Tumors",
    "inclusion_criteria": "* Able to understand and willing to sign the ICF.\n* Male or female subject ≥ 18 years.\n* Histologically/cytologically confirmed, locally advanced unresectable or metastatic solid tumors that are refractory to standard therapy, or for which no standard therapy exists.\n* Subject has measurable disease per RECIST v1.1.\n* ECOG Performance Status 0 to 1\n* Subjects with life expectancy of ≥ 3 month\n* No herbal/alternative medications prior to the first dose\n* Must have adequate hematological, hepatic and renal function as defined in the protocol.\n* Prior anti-tumor therapies of different kinds must have stopped before the first dose as defined by protocol\n* Effective contraception for both male and female subjects if the risk of conception exists\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnant or nursing females.\n* Any remaining AEs > grade 1 from prior anti-tumor treatment as per CTCAE v4. 03, with exception of the residual hair loss;\n* Received a biologic G-CSF, GM-CSF or erythropoietin within 14 days prior to the first dose of study drug;\n* Subjects who had prior treatment with an anti-PD-L1 product\n* History of documented autoimmune disease except for autoimmune hypothyroidism and well-controlled Type 1 diabetes mellitus.\n* W/o autoimmune condition requiring systemic treatment with immunosuppressive medications within 14 days before the planned first dose of study drug.\n* Primacy central nervous system (CNS) malignancy or symptomatic CNS metastases are not allowed, with exceptions defined in protocol.\n* Major surgery within the 28-days from the screening\n* Subjects with idiopathic pulmonary fibrosis or unresolved active or chronic inflammatory pulmonary disease are excluded.\n* History of human immunodeficiency virus (HIV) infection, active hepatitis B or C. HBV carriers\n* History of primary immunodeficiency, stem cell or organ transplant, or previous clinical diagnosis of tuberculosis disease.\n* Clinically significant acute infections 4 weeks and any infection 2 weeks prior to the first dose administration.\n* Known allergies, hypersensitivity, or intolerance to protein-based therapies or with a history of any significant drug allergy\n* Subjects who experienced immunotherapy-related adverse events (irAE) grade ≥ 3, or who had to discontinue prior anti-PD-1 treatment due to irAEs of any grade.\n* Severe or uncontrolled cardiac disease requiring treatment as defined in protocol\n* Any other serious underlying medical, psychiatric, psychological, familial or geographical condition that, in the judgment of the investigator, might impair the subject's benefit from the trial treatment\n* Known history of hypersensitivity to any components of the MSB2311 product.",
    "miscellaneous_criteria": ""
}